DOCSLIB.ORG

External Cephalic Version and Reducing the Incidence of Breech Presentation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
External Cephalic Version and Reducing the Incidence of Breech Presentation Guideline No. 20a December 2006 Reviewed 2010 EXTERNAL CEPHALIC VERSION AND REDUCING THE INCIDENCE OF BREECH PRESENTATION This is the first edition of this guideline. Methods of delivery for women with breech presentation is covered in RCOG Green-top Guideline No. 20b, The Management of Breech Presentation, published in December 2006. 1. Purpose and scope External cephalic version (ECV) is the manipulation of the fetus, through the maternal abdomen, to a cephalic presentation. This guideline summarises the evidence regarding the routine use of ECV for breech presentation. The rationale behind ECV is to reduce the incidence of breech presentation at term and therefore the associated risks, particularly of avoidable caesarean section. The evidence concerning mode and technique of delivery of the persistent breech presentation is summarised in Green-top Guideline No. 20b, The Management of Breech Presentation. 2. Background Breech presentation complicates 3–4% of all term deliveries and a higher proportion of preterm deliveries. It is more common where there has been a previous breech presentation. The incidence of caesarean section for breech presentation has increased markedly in the last 20 years and further1 with the publication of the term breech trial.2 This trial concluded that, at least for mortality and markers of intermediate term morbidity, elective caesarean section was safer for the fetus and of similar safety to the mother when compared with intention to deliver vaginally.3 This means that measures to reduce the incidence of breech presentation have become more important and that the effect of any such measure on the incidence of caesarean section will be more marked. 3. Identification and assessment of evidence Evidence-based medicine reviews, including the Cochrane Register of Controlled Trials, were searched, together with the TRIP database for relevant randomised controlled trials, systematic reviews and meta- analyses. A search of Medline and PubMed (electronic databases) from 1966 to 2005 was also carried out. Search words included ‘breech’, ‘external cephalic version’, ‘fetal’, ‘tocolysis’ and ‘tocolytic agents’ and the search was limited to humans and English language. 4. External cephalic version 4.1 What is the impact of ECV on the incidence of breech presentation at delivery? Women should be counselled that ECV reduces the chance of breech presentation at delivery. A 1 of 8 RCOG Guideline No. 20a ECV at term reduces the incidence of noncephalic presentation at delivery (RR 0.38, 95% CI 4 0.18–0.80, risk difference 52%, NNT 2). Spontaneous version rates for nulliparous women are Evidence approximately 8% after 36 weeks5 but less than 5% after unsuccessful ECV;6 success rates of ECV are level Ia 30–80%. Spontaneous reversion to breech presentation after successful ECV occurs in less than 5%.7,8 4.2 What is the effect of ECV on the caesarean section rate? Women with a breech baby should be informed that attempting ECV lowers their chances of having a A caesarean section. Labour with a cephalic presentation following ECV is associated with a higher rate of obstetric B intervention than when ECV has not been required. ECV reduces the caesarean section rate by lowering the incidence of breech presentation (RR 0.55, 95% CI 0.33–0.91, risk difference 17%, NNT 6).4 Provision of an ECV service also reduces the 9 caesarean section rates for breech presentation. This reduction was not necessarily seen when and Evidence where unidentified breeches were more likely to be delivered vaginally.10 In current practice, level Ia breech babies are increasingly delivered by caesarean section, so the effect is likely to be more marked than the randomised trials.11,12 This reduction is in spite of a two-fold increase in intrapartum caesarean sections for successfully 13,14 turned babies, when compared with babies that were not breech at term. This is independent Evidence of an increased induction rate: both fetal and maternal indications for intervention are implicated.15 level III A small increase in instrumental delivery is also seen. 4.3 What is the success rate of ECV and what influences it? Women should be counselled that, with a trained operator, about 50% of ECV attempts will be B successful but this rate can be individualised for them. Results vary from 30% up to 80% in different series.7,16,17,18 Race, parity, uterine tone, liquor volume, engagement of the breech and whether the head is palpable, and the use of tocolysis, all affect the success rate.18,19 Published individual success rates may vary because of case selection as well as these factors. The highest success rates are seen with multiparous, non-white women with a relaxed 18 Evidence uterus, where the breech is not engaged and the head is easily palpable. Success rates are also level III higher with increasing liquor volume16,20 but, in practice, very high liquor volume may be associated with spontaneous reversion. Maternal weight, placental position, gestation, fetal size and position of the legs make less difference and are probably not independent of other factors.18 An overall success rate of 40% for nulliparous, and 60% for multiparous women can usually be achieved. 4.4 Does the use of tocolysis improve the success rate of ECV? The use of tocolysis with beta-sympathomimetics may be offered to women undergoing ECV as it has A been shown to increase the success rate. The use of tocolysis should be considered where an initial attempt at ECV without tocolysis has failed. P The success rate of ECV is increased by the use of tocolysis. This has been proven with ritodrine, salbutamol and terbutaline but not with glyceryl trinitrate (GTN) as a patch or sublingually,21 or Evidence with nifedipine. Intravenous and subcutaneous routes can be used. Data on those women who level Ia benefit most are contradictory. Tocolysis is also beneficial where an initial attempt without it has failed22 and can be attempted immediately. However, this policy has not been compared to tocolysis RCOG Guideline No. 20a 2 of 8 for all. A simple protocol is to offer a slow intravenous or subcutaneous bolus of salbutamol or Evidence terbutaline either routinely or if an initial ECV attempt has failed. Women should be advised of the level Ia adverse effects of tocolysis with beta-2 agonists. 4.5 What other methods can be used to increase the success rate of ECV? Where ECV fails the possibility of a further attempt should be discussed. P A later, second attempt, particularly with a second operator or where the back has been in the midline, may lead to a small increase in overall success rates but tocolysis markedly increases the success rate at a second attempt if it has not been used first.22 Other methods employed to increase success rates include the application of noise to the abdomen (fetal acoustic stimulation) where the back is in the midline,23 and regional analgesia, including after a failed initial attempt. For the latter, an increase in success rate is evident with epidural but not spinal analgesia.24 As maternal pain might indicate a complication, concerns regarding safety remain. 4.6 When should ECV be offered? ECV should be offered from 36 weeks in nulliparous women and from 37 weeks in multiparous women. B ECV before 36 weeks of gestation is not associated with a significant reduction in noncephalic births or caesarean section.25 However, one controlled trial26 randomised women, where low spontaneous version rates were anticipated, to ECV at 34–36 or at 37–38 weeks of gestation. This demonstrated a non-significant reduction in noncephalic births and caesarean section in the early ECV group, although fewer women in the delayed ECV group underwent an ECV and a larger trial Evidence investigating this is continuing. Importantly, the trial did not show an increased preterm labour rate level IIb and confirmed the safety of early ECV and the low spontaneous reversion rate in this group. With a spontaneous version rate of 8% in nulliparous breeches after 36 weeks of gestation5 and the very low complication rate, ECV from 36 weeks of gestation in nulliparous women therefore seems a reasonable compromise. There is no upper time limit on the appropriate gestation for ECV. Successes has been reported at 42 weeks of gestation7 and can be performed in early labour27 provided that the membranes are intact. 4.7 Is ECV safe? Women should be counselled that ECV has a very low complication rate. B Women should be alerted to potential complications of ECV. P ECV is rarely associated with complications. Nevertheless, a few case reports exist of complications such as placental abruption, uterine rupture and fetomaternal haemorrhage. Randomised controlled trials4 have reported no evidence of an increase in neonatal morbidity and mortality (RR Evidence 0.44, 95% CI 0.07–2.92) but are underpowered for these rare outcomes. Systematic reviews report level III a very low complication rate6,28 but are subject to the limitations of reporting bias. These, and large consecutive series,7,29 however, suggest a 0.5% immediate emergency caesarean section rate and no excess perinatal morbidity and perinatal mortality. ECV does not appear to promote labour7 but is associated with alterations in fetal parameters. These include a fetal bradycardia and a nonreactive cardiotocograph30 that are almost invariably transient, alterations in umbilical artery and middle cerebral artery waveforms31 and an increase in amniotic fluid volume.32 The significance of these is unknown. 3 of 8 RCOG Guideline No. 20a ECV should be performed where facilities for monitoring and immediate delivery are available. P The standard preoperative preparations for caesarean section are not necessary for women undergoing ECV. P ECV should be performed where ultrasound to enable fetal heart rate visualisation, cardiotocography and theatre facilities are available.
Load more

Recommended publications
  • The Diagnostic Impact of Limited, Screening Obstetric Ultrasound When Performed by Midwives in Rural Uganda
    Journal of Perinatology (2014) 34, 508–512 © 2014 Nature America, Inc. All rights reserved 0743-8346/14 www.nature.com/jp ORIGINAL ARTICLE The diagnostic impact of limited, screening obstetric ultrasound when performed by midwives in rural Uganda JO Swanson1, MG Kawooya2, DL Swanson1, DS Hippe1, P Dungu-Matovu2 and R Nathan1 OBJECTIVE: To evaluate the diagnostic impact of limited obstetric ultrasound (US) in identifying high-risk pregnancies when used as a screening tool by midwives in rural Uganda. STUDY DESIGN: This was an institutional review board-approved prospective study of expecting mothers in rural Uganda who underwent clinical and US exams as part of their standard antenatal care visit in a local health center in the Isingiro district of Uganda. The midwives documented clinical impressions before performing a limited obstetric US on the same patient. The clinical findings were then compared with the subsequent US findings to determine the diagnostic impact. The midwives were US-naive before participating in the 6-week training course for limited obstetric US. RESULT: Midwife-performed screening obstetric US altered the clinical diagnosis in up to 12% clinical encounters. This diagnostic impact is less (6.7 to 7.4%) if the early third trimester diagnosis of malpresentation is excluded. The quality assurance review of midwives’ imaging demonstrated 100% sensitivity and specificity in the diagnosing gestational number, and 90% sensitivity and 96% specificity in the diagnosis of fetal presentation. CONCLUSION: Limited, screening obstetric US performed by midwives with focused, obstetric US training demonstrates the diagnostic impact for identifying conditions associated with high-risk pregnancies in 6.7 to 12% of patients screened.
    [Show full text]
  • Breech Presentation at Delivery: a Marker for Congenital Anomaly?
    Journal of Perinatology (2014) 34, 11–15 & 2014 Nature America, Inc. All rights reserved 0743-8346/14 www.nature.com/jp ORIGINAL ARTICLE Breech presentation at delivery: a marker for congenital anomaly? D Mostello1, JJ Chang2, F Bai2, J Wang3, C Guild4, K Stamps2 and TL Leet2,{ OBJECTIVE: To determine whether congenital anomalies are associated with breech presentation at the time of birth. STUDY DESIGN: A population-based, retrospective cohort study was conducted among 460 147 women with singleton live births using the Missouri Birth Defects Registry, which includes all defects diagnosed during the first year of life. Maternal and obstetric characteristics and outcomes between breech and cephalic presentation groups were compared using w2-square statistic and Student’s t-test. Multivariable binary logistic regression analysis was used to estimate adjusted odds ratios (aORs) and 95% confidence intervals (CIs). RESULT: At least one congenital anomaly was more likely present among infants breech at birth (11.7%) than in those with cephalic presentation (5.1%), whether full-term (9.4 vs 4.6%) or preterm (20.1 vs 11.6%). The relationship between breech presentation and congenital anomaly was stronger among full-term births (aOR 2.09, CI 1.96, 2.23, term vs 1.40, CI 1.26, 1.55, preterm), but not in all categories of anomalies. CONCLUSION: Breech presentation at delivery is a marker for the presence of congenital anomaly. Infants delivered breech deserve special scrutiny for the presence of malformation. Journal of Perinatology (2014) 34, 11–15;
    [Show full text]
  • A Guide to Obstetrical Coding Production of This Document Is Made Possible by Financial Contributions from Health Canada and Provincial and Territorial Governments
    ICD-10-CA | CCI A Guide to Obstetrical Coding Production of this document is made possible by financial contributions from Health Canada and provincial and territorial governments. The views expressed herein do not necessarily represent the views of Health Canada or any provincial or territorial government. Unless otherwise indicated, this product uses data provided by Canada’s provinces and territories. All rights reserved. The contents of this publication may be reproduced unaltered, in whole or in part and by any means, solely for non-commercial purposes, provided that the Canadian Institute for Health Information is properly and fully acknowledged as the copyright owner. Any reproduction or use of this publication or its contents for any commercial purpose requires the prior written authorization of the Canadian Institute for Health Information. Reproduction or use that suggests endorsement by, or affiliation with, the Canadian Institute for Health Information is prohibited. For permission or information, please contact CIHI: Canadian Institute for Health Information 495 Richmond Road, Suite 600 Ottawa, Ontario K2A 4H6 Phone: 613-241-7860 Fax: 613-241-8120 www.cihi.ca [email protected] © 2018 Canadian Institute for Health Information Cette publication est aussi disponible en français sous le titre Guide de codification des données en obstétrique. Table of contents About CIHI ................................................................................................................................. 6 Chapter 1: Introduction ..............................................................................................................
    [Show full text]
  • Twin Pregnancy with Triploidy and Co-Existing Live Twin Progressing to Viability: Case Study and Literature Review
    Obstetrics & Gynecology International Journal Case Report Open Access Twin pregnancy with triploidy and co-existing live twin progressing to viability: Case study and literature review Abstract Volume 9 Issue 4 - 2018 Background: Twin pregnancies consisting of a triploid fetus with molar change and a 1,2 1,2 1,2 healthy coexisting fetus is an extremely rare phenomenon. Triploidy rarely advances to the Cingiloglu P, Yeung T, Sekar R second trimester, most resulting in a miscarriage, termination or stillbirth. Only five cases 1Royal Brisbane and Women’s Hospital, Women’s and Newborn of a triploid fetus and a healthy co-twin have been reported in literature. We present the first Services, Australia documented case of a live delivery of both triploid fetus and coexisting viable twin. 2University of Queensland, Australia Case presentation: A 23-year old woman, gravida 2, para 1 was admitted at 26+4 weeks Correspondence: Pinar Cingiloglu, Women’s and Newborn gestation with DCDA twins and a shortened cervix. Sonography revealed polyhydramnios, Services, Royal Brisbane and Women’s Hospital, Bowen Bridge an abnormal cystic placenta, and small aortic valve for the presenting twin. Emergency Road&, Butterfield St, Herston Queensland Australia, Tel +61 caesarean section was performed at 28 weeks gestation for cord prolapse. Twin A was born (07) 3646 8111, Email [email protected] a live infant with ambiguous genitalia, syndactyly, epicanthic folds and cerebral cysts. Twin B was born a healthy live male. Histopathology revealed features consistent with Received: June 13, 2018 | Published: July 13, 2018 partial hydatidiform mole, and cytogenetics revealed a diandric triploidy in twin A.
    [Show full text]
  • Gtg-No-20B-Breech-Presentation.Pdf
    Guideline No. 20b December 2006 THE MANAGEMENT OF BREECH PRESENTATION This is the third edition of the guideline originally published in 1999 and revised in 2001 under the same title. 1. Purpose and scope The aim of this guideline is to provide up-to-date information on methods of delivery for women with breech presentation. The scope is confined to decision making regarding the route of delivery and choice of various techniques used during delivery. It does not include antenatal or postnatal care. External cephalic version is the topic of a separate RCOG Green-top Guideline No. 20a: ECV and Reducing the Incidence of Breech Presentation. 2. Background The incidence of breech presentation decreases from about 20% at 28 weeks of gestation to 3–4% at term, as most babies turn spontaneously to the cephalic presentation. This appears to be an active process whereby a normally formed and active baby adopts the position of ‘best fit’ in a normal intrauterine space. Persistent breech presentation may be associated with abnormalities of the baby, the amniotic fluid volume, the placental localisation or the uterus. It may be due to an otherwise insignificant factor such as cornual placental position or it may apparently be due to chance. There is higher perinatal mortality and morbidity with breech than cephalic presentation, due principally to prematurity, congenital malformations and birth asphyxia or trauma.1,2 Caesarean section for breech presentation has been suggested as a way of reducing the associated perinatal problems2,3 and in many countries in Northern Europe and North America caesarean section has become the normal mode of breech delivery.
    [Show full text]
  • Advising Women with Diabetes in Pregnancy to Express Breastmilk In
    Articles Advising women with diabetes in pregnancy to express breastmilk in late pregnancy (Diabetes and Antenatal Milk Expressing [DAME]): a multicentre, unblinded, randomised controlled trial Della A Forster, Anita M Moorhead, Susan E Jacobs, Peter G Davis, Susan P Walker, Kerri M McEgan, Gillian F Opie, Susan M Donath, Lisa Gold, Catharine McNamara, Amanda Aylward, Christine East, Rachael Ford, Lisa H Amir Summary Lancet 2017; 389: 2204–13 Background Infants of women with diabetes in pregnancy are at increased risk of hypoglycaemia, admission to a See Editorial page 2163 neonatal intensive care unit (NICU), and not being exclusively breastfed. Many clinicians encourage women with See Comment page 2167 diabetes in pregnancy to express and store breastmilk in late pregnancy, yet no evidence exists for this practice. We Judith Lumley Centre, School of aimed to determine the safety and efficacy of antenatal expressing in women with diabetes in pregnancy. Nursing and Midwifery, La Trobe University, Methods We did a multicentre, two-group, unblinded, randomised controlled trial in six hospitals in Victoria, Australia. Melbourne, VIC, Australia (Prof D A Forster PhD, We recruited women with pre-existing or gestational diabetes in a singleton pregnancy from 34 to 37 weeks’ gestation A M Moorhead RM, and randomly assigned them (1:1) to either expressing breastmilk twice per day from 36 weeks’ gestation (antenatal L H Amir PhD); Royal Women’s expressing) or standard care (usual midwifery and obstetric care, supplemented by support from a diabetes educator). Hospital, Parkville, VIC, Randomisation was done with a computerised random number generator in blocks of size two and four, and was Australia (Prof D A Forster, A M Moorhead, S E Jacobs MD, stratified by site, parity, and diabetes type.
    [Show full text]
  • Cord Prolapse
    CLINICAL PRACTICE GUIDELINE CORD PROLAPSE CLINICAL PRACTICE GUIDELINE CORD PROLAPSE Institute of Obstetricians and Gynaecologists, Royal College of Physicians of Ireland and the Clinical Strategy and Programmes Division, Health Service Executive Version: 1.0 Publication date: March 2015 Guideline No: 35 Revision date: March 2017 1 CLINICAL PRACTICE GUIDELINE CORD PROLAPSE Table of Contents 1. Revision History ................................................................................ 3 2. Key Recommendations ....................................................................... 3 3. Purpose and Scope ............................................................................ 3 4. Background and Introduction .............................................................. 4 5. Methodology ..................................................................................... 4 6. Clinical Guidelines on Cord Prolapse…… ................................................ 5 7. Hospital Equipment and Facilities ....................................................... 11 8. References ...................................................................................... 11 9. Implementation Strategy .................................................................. 14 10. Qualifying Statement ....................................................................... 14 11. Appendices ..................................................................................... 15 2 CLINICAL PRACTICE GUIDELINE CORD PROLAPSE 1. Revision History Version No.
    [Show full text]
  • Tractocile, Atosiban
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Tractocile 6.75 mg/0.9 ml solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial of 0.9 ml solution contains 6.75 mg atosiban (as acetate). For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection (injection). Clear, colourless solution without particles. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Tractocile is indicated to delay imminent pre-term birth in pregnant adult women with: regular uterine contractions of at least 30 seconds duration at a rate of 4 per 30 minutes a cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of 50% a gestational age from 24 until 33 completed weeks a normal foetal heart rate 4.2 Posology and method of administration Posology Treatment with Tractocile should be initiated and maintained by a physician experienced in the treatment of pre-term labour. Tractocile is administered intravenously in three successive stages: an initial bolus dose (6.75 mg), performed with Tractocile 6.75 mg/0.9 ml solution for injection, immediately followed by a continuous high dose infusion (loading infusion 300 micrograms/min) of Tractocile 37.5 mg/5 ml concentrate for solution for infusion during three hours, followed by a lower dose of Tractocile 37.5 mg/5 ml concentrate for solution for infusion (subsequent infusion 100 micrograms/min) up to 45 hours. The duration of the treatment should not exceed 48 hours. The total dose given during a full course of Tractocile therapy should preferably not exceed 330.75 mg of atosiban.
    [Show full text]
  • Tocolytics Used As Adjunctive Therapy at the Time of Cerclage Placement: a Systematic Review
    Journal of Perinatology (2015) 35, 561–565 © 2015 Nature America, Inc. All rights reserved 0743-8346/15 www.nature.com/jp ORIGINAL ARTICLE Tocolytics used as adjunctive therapy at the time of cerclage placement: a systematic review J Smith1,2 and EA DeFranco3,4 OBJECTIVE: To review the published literature on whether the use of empiric perioperative tocolytic medications could provide additional benefit when used in combination with cerclage. STUDY DESIGN: Systematic review of published medical literature reporting the efficacy of empiric tocolytics used as a perioperative adjunct to vaginal cerclage in high-risk patients. A PubMed search without date criteria of various tocolytics and cerclage yielded 42 studies. Review articles were excluded, as were reports of abdominal cerclage, emergent cerclage, or cerclage for the purpose of delayed interval delivery in twin gestations. RESULT: Only five publications on the topic of perioperative tocolytic use at the time of history or ultrasound-indicated vaginal cerclage placement were identified. These included zero clinical trials, three retrospective cohort studies, one case series and one case report. Only one cohort study compared cerclage with indomethacin and cerclage without indomethacin and suggested no difference between the groups. The other two published cohort studies had no referent group who received cerclage without tocolysis. One case series and one case report were also published reporting cerclage with empiric beta-mimetic and progesterone adjunctive therapy. CONCLUSION: There is a paucity of published data on the topic of adjunctive perioperative tocolytics with cerclage. Adequately powered clinical trials on perioperative use of tocolysis with cerclage compared with a standard cerclage placement alone are needed to establish efficacy.
    [Show full text]
  • Pharmaceutical Services Division and the Clinical Research Centre Ministry of Health Malaysia
    A publication of the PHARMACEUTICAL SERVICES DIVISION AND THE CLINICAL RESEARCH CENTRE MINISTRY OF HEALTH MALAYSIA MALAYSIAN STATISTICS ON MEDICINES 2008 Edited by: Lian L.M., Kamarudin A., Siti Fauziah A., Nik Nor Aklima N.O., Norazida A.R. With contributions from: Hafizh A.A., Lim J.Y., Hoo L.P., Faridah Aryani M.Y., Sheamini S., Rosliza L., Fatimah A.R., Nour Hanah O., Rosaida M.S., Muhammad Radzi A.H., Raman M., Tee H.P., Ooi B.P., Shamsiah S., Tan H.P.M., Jayaram M., Masni M., Sri Wahyu T., Muhammad Yazid J., Norafidah I., Nurkhodrulnada M.L., Letchumanan G.R.R., Mastura I., Yong S.L., Mohamed Noor R., Daphne G., Kamarudin A., Chang K.M., Goh A.S., Sinari S., Bee P.C., Lim Y.S., Wong S.P., Chang K.M., Goh A.S., Sinari S., Bee P.C., Lim Y.S., Wong S.P., Omar I., Zoriah A., Fong Y.Y.A., Nusaibah A.R., Feisul Idzwan M., Ghazali A.K., Hooi L.S., Khoo E.M., Sunita B., Nurul Suhaida B.,Wan Azman W.A., Liew H.B., Kong S.H., Haarathi C., Nirmala J., Sim K.H., Azura M.A., Asmah J., Chan L.C., Choon S.E., Chang S.Y., Roshidah B., Ravindran J., Nik Mohd Nasri N.I., Ghazali I., Wan Abu Bakar Y., Wan Hamilton W.H., Ravichandran J., Zaridah S., Wan Zahanim W.Y., Kannappan P., Intan Shafina S., Tan A.L., Rohan Malek J., Selvalingam S., Lei C.M.C., Ching S.L., Zanariah H., Lim P.C., Hong Y.H.J., Tan T.B.A., Sim L.H.B, Long K.N., Sameerah S.A.R., Lai M.L.J., Rahela A.K., Azura D., Ibtisam M.N., Voon F.K., Nor Saleha I.T., Tajunisah M.E., Wan Nazuha W.R., Wong H.S., Rosnawati Y., Ong S.G., Syazzana D., Puteri Juanita Z., Mohd.
    [Show full text]
  • Indomethacin in Pregnancy: Applications and Safety
    Original Article 175 Indomethacin in Pregnancy: Applications and Safety Gael Abou-Ghannam, M.D. 1 Ihab M. Usta, M.D. 1 Anwar H. Nassar, M.D. 1 1 Department of Obstetrics and Gynecology, American University of Address for correspondence and reprint requests Anwar H. Nassar, Beirut Medical Center, Hamra, Beirut, Lebanon M.D., American University of Beirut Medical Center, P.O. Box 113-6044/B36, Hamra 110 32090, Beirut, Lebanon (e-mail: [email protected]). Am J Perinatol 2012;29:175–186. Abstract Preterm labor (PTL) is a major cause of neonatal morbidity and mortality worldwide. Among the available tocolytics, indomethacin, a prostaglandin synthetase inhibitor, has been in use since the 1970s. Recent studies have suggested that prostaglandin synthetase inhibitors are superior to other tocolytics in delaying delivery for 48 hours and 7 days. However, increased neonatal complications including oligohydramnios, Keywords renal failure, necrotizing enterocolitis, intraventricular hemorrhage, and closure of the ► indomethacin patent ductus arteriosus have been reported with the use of indomethacin. Indometh- ► tocolysis acin has been also used in women with short cervices as well as in those with idiopathic ► preterm labor polyhydramnios. This article describes the mechanism of action of indomethacin and its ► short cervix clinical applications as a tocolytic agent in women with PTL and cerclage and its use in ► polyhydramnios the context of polyhydramnios. The fetal and neonatal side effects of this drug are also ► fetal side effects summarized and guidelines for its use are proposed. Preterm labor (PTL) is a major cause of neonatal morbidity in women with PTL and cerclage and its use in the context of and mortality worldwide.1 Care of premature infants has polyhydramnios.
    [Show full text]
  • Tocolytic Therapy a Meta-Analysis and Decision Analysis
    Tocolytic Therapy A Meta-Analysis and Decision Analysis David M. Haas, MD, MS, Thomas F. Imperiale, MD, Page R. Kirkpatrick, Robert W. Klein, Terrell W. Zollinger, DrPH, and Alan M. Golichowski, MD, PhD OBJECTIVE: To determine the optimal first-line tocolytic ing prostaglandin inhibitors, only 80 would deliver within agent for treatment of premature labor. 48 hours, compared with 182 for the next-best treatment. METHODS: We performed a quantitative analysis of ran- CONCLUSION: Although all current tocolytic agents domized controlled trials of tocolysis, extracting data on were superior to no treatment at delaying delivery for maternal and neonatal outcomes, and pooling rates for both 48 hours and 7 days, prostaglandin inhibitors were each outcome across trials by treatment. Outcomes were superior to the other agents and may be considered the delay of delivery for 48 hours, 7 days, and until 37 weeks; optimal first-line agent before 32 weeks of gestation to adverse effects causing discontinuation of therapy; absence delay delivery. of respiratory distress syndrome; and neonatal survival. We (Obstet Gynecol 2009;113:585–94) used weighted proportions from a random-effects meta- analysis in a decision model to determine the optimal first-line tocolytic therapy. Sensitivity analysis was per- reterm birth, defined as any birth before the gesta- formed using the standard errors of the weighted propor- Ptional age of 37 weeks, is responsible for most of the 1–3 tions. neonatal morbidity and mortality in the United States and consumes 35% of all U.S. healthcare spending on RESULTS: Fifty-eight studies satisfied the inclusion crite- 4 ria.
    [Show full text]